Posted On: 09/10/2015 3:32:00 PM
Post# of 72440
Re: daydreaming2 #13594
B-OM hasn't been granted rolling review yet. It's potential competitor, SGX942, was granted fast track. I expect the same designation for B-OM.
Leo said the trial has an adaptive design, which means it could turn into a P3 during P2. But this information hasn't made public yet.
http://investorshangout.com/post/view?id=2995833
Leo said the trial has an adaptive design, which means it could turn into a P3 during P2. But this information hasn't made public yet.
http://investorshangout.com/post/view?id=2995833
Quote:
correct me if I'm wrong but isn't the B-OM trial on a rolling review also.
(0)
(0)
Scroll down for more posts ▼
